News
BNXTF
0.400
NaN%
--
BioNxt Solutions Addresses MCTO Status Amid Filing Delays
TipRanks · 3d ago
Weekly Report: what happened at BNXTF last week (0602-0606)?
Weekly Report · 6d ago
Weekly Report: what happened at BNXTF last week (0526-0530)?
Weekly Report · 06/02 10:01
BioNxt Solutions Receives Management Cease Trade Order Amidst Filing Delays
TipRanks · 05/29 22:08
BioNxt Solutions Secures Key European Patent for Sublingual Drug Delivery
TipRanks · 05/26 14:32
Weekly Report: what happened at BNXTF last week (0519-0523)?
Weekly Report · 05/26 10:01
Weekly Report: what happened at BNXTF last week (0512-0516)?
Weekly Report · 05/19 09:57
BioNxt Solutions Provides Update on Management Cease Trade Order
TipRanks · 05/15 21:54
BioNxt Expands R&D Capabilities with Munich Lab Integration
TipRanks · 05/14 20:03
Weekly Report: what happened at BNXTF last week (0505-0509)?
Weekly Report · 05/12 09:57
BioNxt Solutions Secures Eurasian Patent for Sublingual Drug Delivery
TipRanks · 05/05 17:04
Weekly Report: what happened at BNXTF last week (0428-0502)?
Weekly Report · 05/05 09:58
BioNxt Solutions Delays 2024 Financial Statement Filing
TipRanks · 05/02 00:08
Weekly Report: what happened at BNXTF last week (0421-0425)?
Weekly Report · 04/28 10:02
BioNxt Solutions Advances Human Bioequivalence Study for MS Treatment
TipRanks · 04/23 16:38
Weekly Report: what happened at BNXTF last week (0414-0418)?
Weekly Report · 04/21 10:02
Weekly Report: what happened at BNXTF last week (0407-0411)?
Weekly Report · 04/14 09:57
Weekly Report: what happened at BNXTF last week (0331-0404)?
Weekly Report · 04/07 09:57
Weekly Report: what happened at BNXTF last week (0324-0328)?
Weekly Report · 03/31 10:02
Weekly Report: what happened at BNXTF last week (0317-0321)?
Weekly Report · 03/24 09:57
More
Webull provides a variety of real-time BNXTF stock news. You can receive the latest news about BioNxt Solutions Inc through multiple platforms. This information may help you make smarter investment decisions.
About BNXTF
BioNxt Solutions Inc. is a bioscience company. The Company is focused on drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical ingredient investment opportunities, including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany. The Company is also focused on regulatory approval and commercialization of medical products for European markets. Its diagnostic products include COVID-19 PCR Diagnostic Kit, Peri-Implantitis Oral Biosensor, and H1N1 (Swine Flu) and H5N1 (Avian Flu) Oral Biosensors. Its subsidiaries include XPhyto Laboratories Inc., Bunker Pflanzenextrakte GmbH, Vektor Pharma TF GmbH, BioNxt Europe GmbH, and 3a-diagnostics GmbH, among others.